These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
359 related articles for article (PubMed ID: 26756903)
1. Hippocampal harms, protection and recovery following regular cannabis use. Yücel M; Lorenzetti V; Suo C; Zalesky A; Fornito A; Takagi MJ; Lubman DI; Solowij N Transl Psychiatry; 2016 Jan; 6(1):e710. PubMed ID: 26756903 [TBL] [Abstract][Full Text] [Related]
2. A randomised controlled trial of vaporised Δ Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105 [TBL] [Abstract][Full Text] [Related]
3. Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol. Demirakca T; Sartorius A; Ende G; Meyer N; Welzel H; Skopp G; Mann K; Hermann D Drug Alcohol Depend; 2011 Apr; 114(2-3):242-5. PubMed ID: 21050680 [TBL] [Abstract][Full Text] [Related]
4. Dissociable effects of cannabis with and without cannabidiol on the human brain's resting-state functional connectivity. Wall MB; Pope R; Freeman TP; Kowalczyk OS; Demetriou L; Mokrysz C; Hindocha C; Lawn W; Bloomfield MA; Freeman AM; Feilding A; Nutt D; Curran HV J Psychopharmacol; 2019 Jul; 33(7):822-830. PubMed ID: 31013455 [TBL] [Abstract][Full Text] [Related]
6. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Morgan CJ; Gardener C; Schafer G; Swan S; Demarchi C; Freeman TP; Warrington P; Rupasinghe I; Ramoutar A; Tan N; Wingham G; Lewis S; Curran HV Psychol Med; 2012 Feb; 42(2):391-400. PubMed ID: 21798112 [TBL] [Abstract][Full Text] [Related]
7. Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users. Beale C; Broyd SJ; Chye Y; Suo C; Schira M; Galettis P; Martin JH; Yücel M; Solowij N Cannabis Cannabinoid Res; 2018; 3(1):94-107. PubMed ID: 29682609 [No Abstract] [Full Text] [Related]
8. The Role of Cannabinoids in Neuroanatomic Alterations in Cannabis Users. Lorenzetti V; Solowij N; Yücel M Biol Psychiatry; 2016 Apr; 79(7):e17-31. PubMed ID: 26858212 [TBL] [Abstract][Full Text] [Related]
9. Cannabis, cannabidiol, and epilepsy--from receptors to clinical response. Szaflarski JP; Bebin EM Epilepsy Behav; 2014 Dec; 41():277-82. PubMed ID: 25282526 [TBL] [Abstract][Full Text] [Related]
10. Regional brain abnormalities associated with long-term heavy cannabis use. Yücel M; Solowij N; Respondek C; Whittle S; Fornito A; Pantelis C; Lubman DI Arch Gen Psychiatry; 2008 Jun; 65(6):694-701. PubMed ID: 18519827 [TBL] [Abstract][Full Text] [Related]
11. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914 [TBL] [Abstract][Full Text] [Related]
12. THC and CBD in blood samples and seizures in Norway: Does CBD affect THC-induced impairment in apprehended subjects? Havig SM; Høiseth G; Strand MC; Karinen RA; Brochmann GW; Strand DH; Bachs L; Vindenes V Forensic Sci Int; 2017 Jul; 276():12-17. PubMed ID: 28463706 [TBL] [Abstract][Full Text] [Related]
13. [Nabiximols as a substitute for cannabis]. Dumont GJH Ned Tijdschr Geneeskd; 2020 Sep; 164():. PubMed ID: 33201625 [TBL] [Abstract][Full Text] [Related]
14. The yin and yang of cannabis-induced psychosis: the actions of Δ(9)-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia. Arnold JC; Boucher AA; Karl T Curr Pharm Des; 2012; 18(32):5113-30. PubMed ID: 22716133 [TBL] [Abstract][Full Text] [Related]
15. Medical use of cannabis. Cannabidiol: a new light for schizophrenia? Deiana S Drug Test Anal; 2013 Jan; 5(1):46-51. PubMed ID: 23109356 [TBL] [Abstract][Full Text] [Related]
16. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. Allsop DJ; Copeland J; Lintzeris N; Dunlop AJ; Montebello M; Sadler C; Rivas GR; Holland RM; Muhleisen P; Norberg MM; Booth J; McGregor IS JAMA Psychiatry; 2014 Mar; 71(3):281-91. PubMed ID: 24430917 [TBL] [Abstract][Full Text] [Related]
17. Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15. Niesink RJ; Rigter S; Koeter MW; Brunt TM Addiction; 2015 Dec; 110(12):1941-50. PubMed ID: 26234170 [TBL] [Abstract][Full Text] [Related]